Ticker brief
ABBV ABBVIE INC
Consumer, Non-cyclical · Pharmaceuticals
last close
$255.48
1 day
-1.0%
14 days
+2.4%
mkt cap
$461.3B
signals 14d
47
authors 14d
31
crowd 14d
+1.0σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 28% mid · 69 pctile own 1y | IV/HV 0.93× (as of 2026-07-31) |
| Skew — 25Δ RR 30d | -0.009 95 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +0.46 elevated | 5-session Δ -0.02 (as of 2026-07-06) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-28 · now +0.00 (−1 bearish … +1 bullish)
Who spoke31
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | -0.45 | 8 | +0.06 |
| @ResearchPulse1 | B | +1.48 | 6 | +0.28 |
| @TalkMarkets | C | · | 2 | +0.40 |
| @BeyondOption | B | · | 2 | +0.12 |
| @EdwardAlerts | C | -0.65 | 2 | +0.75 |
| @kpak82 | C | -0.13 | 2 | -0.38 |
| @investseekers | B | -0.65 | 1 | +0.10 |
| @Trading_Sunset | C | -0.52 | 1 | +0.55 |
| @johnscharts | C | -2.20 | 1 | +0.40 |
| @AponiaAnalytics | B | +4.91 | 1 | +0.00 |
| @StockWorthyApp | C | +0.41 | 1 | +0.00 |
| @Ben1148x2 | C | +1.01 | 1 | -0.20 |
| @AsafNaamani | C | -3.38 | 1 | +0.55 |
| @jbulltard1 | C | +0.26 | 1 | +0.30 |
| @VictorG_bolsa | C | +1.59 | 1 | +0.55 |
| @TheMarket_Monk | C | -1.30 | 1 | +0.65 |
| @MrTrendwatch | C | -2.01 | 1 | +0.70 |
| @earnings_watch | B | -1.99 | 1 | +0.30 |
| @TheETFTracker | C | -0.94 | 1 | +0.00 |
| @SmartReversals | C | -0.71 | 1 | +0.50 |
| @CNBCMorningCall | C | -0.17 | 1 | +0.40 |
| @ohiain | C | -4.04 | 1 | +0.55 |
| @harmongreg | B | +0.34 | 1 | +0.00 |
| @1000xStocks | C | +1.09 | 1 | +0.50 |
| @aboutheoptions | C | · | 1 | +0.60 |
Recent signals30of 47 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @bioinvestor24 | +0.00 | Frames SYRE as a broad platform positioned to compete with major immunology companies and exceed peer disease breadth. | — | tweet ↗ |
| 2026-08-27 | @kpak82 | +0.00 | Ticker and daily chart only; stance requires the unseen image. | -1.0% | tweet ↗ |
| 2026-08-27 | @OzmosiHealth | +0.15 | AbbVie submitted an EMA regulatory application for SKYRIZI induction therapy. | -1.0% | tweet ↗ |
| 2026-08-27 | @CrweWorld | +0.10 | AbbVie submitted an EMA application for subcutaneous SKYRIZI induction in Crohn's disease. | -1.0% | tweet ↗ |
| 2026-08-26 | @bioinvestor24 | -0.15 | Argues AbbVie must use its expanded market capitalization or borrowing capacity to pursue major growth. | -2.8% | tweet ↗ |
| 2026-08-26 | @EdwardAlerts | +0.70 | Claims completed gains across six tickers over two weeks. | -2.8% | tweet ↗ |
| 2026-08-26 | @kpak82 | -0.75 | Warns that buying ABBV at its all-time high placed longs at major resistance. | -2.8% | tweet ↗ |
| 2026-08-26 | @cfaryanoconnell | -0.85 | Enter ABBV Aug. 28 $257.50 puts at $1.04 with high confidence. — Explicit bearish put setup with strike, expiry and premium. | -2.8% | tweet ↗ |
| 2026-08-26 | @ResearchPulse1 | +0.45 | Argues mono-amylin drugs have superior tolerability and a large market, citing ABBV's $350M upfront deal. | -2.8% | tweet ↗ |
| 2026-08-26 | @capestrategico | +0.65 | Calls ABBV and LLY top healthcare setups, citing yearly-high volume and bullish moving averages. | -2.8% | tweet ↗ |
| 2026-08-26 | @ResearchPulse1 | +0.45 | Argues low-GI amylins address GLP-1 discontinuation and cites ABBV-295's efficacy and monthly dosing. | -2.8% | tweet ↗ |
| 2026-08-25 | @ResearchPulse1 | +0.25 | Gubra receives a $50M ABBV milestone as ABBV-295 enters Phase II obesity testing. | -3.9% | tweet ↗ |
| 2026-08-25 | @MartyChargin | +0.35 | Large-cap drug stocks are performing well, with LLY singled out as ready for a stronger move. | -3.9% | tweet ↗ |
| 2026-08-25 | @ResearchPulse1 | +0.30 | Argues Gubra's UCN2 fits AbbVie's combination strategy and could make Gubra an M&A target on better terms. | -3.9% | tweet ↗ |
| 2026-08-25 | @StableBread | +0.00 | Uses Teva patent precedents and biotech acquisitions to frame major strategic upside for RVPH. | -3.9% | tweet ↗ |
| 2026-08-24 | @aboutheoptions | +0.60 | Reports 5,000 long-dated ABBV calls expressing a large bullish bet. | -3.4% | tweet ↗ |
| 2026-08-24 | @bioinvestor24 | +0.20 | Suggests expanded market caps give AMGN and ABBV capacity for stock-funded acquisitions. | -3.4% | tweet ↗ |
| 2026-08-24 | @TalkMarkets | +0.45 | States momentum is rotating into biotechnology and healthcare. | -3.4% | tweet ↗ |
| 2026-08-24 | @1000xStocks | +0.50 | Presents ABBV as a dividend-growth holding supported by Skyrizi and Rinvoq. | -3.4% | tweet ↗ |
| 2026-08-24 | @BeyondOption | -0.30 | Flags extreme ABBV GEX/DEX positioning as a potential local maximum. | -3.4% | tweet ↗ |
| 2026-08-24 | @harmongreg | +0.00 | Promotes four AbbVie trade ideas but provides no visible entries or direction. | -3.4% | tweet ↗ |
| 2026-08-24 | @ohiain | +0.55 | Watchlist identifies bullish breakout structures in ABBV and OSCR within a strong healthcare sector. | -3.4% | tweet ↗ |
| 2026-08-24 | @CNBCMorningCall | +0.40 | Barclays says biotech momentum is improving as M&A, capital markets and breakthroughs accelerate. | -3.4% | tweet ↗ |
| 2026-08-24 | @ResearchPulse1 | +0.10 | Roche signed a $2.3 billion obesity-drug deal, with the author seeing positive read-through for Gubra. | -3.4% | tweet ↗ |
| 2026-08-23 | @SmartReversals | +0.50 | Recaps last week's completed bullish and bearish screening outcomes with percentage moves. | -3.6% | tweet ↗ |
| 2026-08-23 | @bioinvestor24 | +0.00 | Detailed biotech framework sees GPCR undervalued but flags clinical and liver-toxicity risks across obesity assets. | -3.6% | tweet ↗ |
| 2026-08-22 | @TheETFTracker | +0.00 | Lists DGRO's top holdings and portfolio weights. | -3.6% | tweet ↗ |
| 2026-08-21 | @EdwardAlerts | +0.80 | Advertises large gains already achieved across six tickers over two weeks. | -3.6% | tweet ↗ |
| 2026-08-21 | @earnings_watch | +0.30 | Recaps a completed ABBV inverse-butterfly paper trade that returned about 13.6%. | -3.6% | tweet ↗ |
| 2026-08-20 | @bioinvestor24 | +0.25 | Views ABBV's three-month injection as competitively ahead while criticizing an unnamed rival's valuation and timeline. | -2.4% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.